Apogee Therapeutics (APGE) Interest Expenses (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Interest Expenses of $268.2 million for Q1 2026, up 681450.39% year-over-year from N/an in Q1 2025, and up 24.05% quarter-over-quarter from $216.2 million in Q4 2025.
Apogee Therapeutics (APGE) Interest Expenses (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Interest Expenses for 5 consecutive years, with $268.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 681450.39% year-over-year to $268.2 million; the TTM figure through Mar 2026 stood at $268.2 million (up 681450.39% YoY), while the FY2025 annual figure was $216.2 million, up 184.12% from the prior year.
- Interest Expenses grew to $268.2 million in Q1 2026 per APGE's latest filing, from $216.2 million in the prior quarter.
- Across five years, Interest Expenses topped out at $268.2 million in Q1 2026 and bottomed at $39345.0 in Q1 2025.
- Historically, Interest Expenses has averaged $68.0 million across 5 years, with a median of $37.1 million in 2023.
- Annual changes were most pronounced in 2025 — Interest Expenses plunged 99.97% — and 2026, when it jumped 681450.39%.
- Apogee Therapeutics' Interest Expenses stood at $6.7 million in 2022, then jumped by 351.56% to $30.2 million in 2023, then jumped by 152.11% to $76.1 million in 2024, then soared by 184.12% to $216.2 million in 2025, then grew by 24.05% to $268.2 million in 2026.
- Business Quant data shows APGE's Interest Expenses at $268.2 million in Q1 2026, $216.2 million in Q4 2025, and $43.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 268.16 Mn |
| Mar 31, 2026 | 268.16 Mn |
| Dec 31, 2025 | 216.17 Mn |
| Dec 31, 2025 | 216.17 Mn |
| Sep 30, 2025 | 43.93 Mn |
| Sep 30, 2025 | 43.93 Mn |
| Jun 30, 2025 | 57.20 Mn |
| Jun 30, 2025 | 57.20 Mn |
| Mar 31, 2025 | 39,345.00 |
| Mar 31, 2025 | 39,345.00 |
| Dec 31, 2024 | 76.08 Mn |
| Dec 31, 2024 | 76.08 Mn |
| Sep 30, 2024 | 102,974.00 |
| Sep 30, 2024 | 102,974.00 |
| Jun 30, 2024 | 46,412.00 |
| Jun 30, 2024 | 46,412.00 |
| Mar 31, 2024 | 115.69 Mn |
| Mar 31, 2024 | 115.69 Mn |
| Dec 31, 2023 | 30.18 Mn |
| Dec 31, 2023 | 30.18 Mn |